Stem cell therapy has emerged as a promising approach to treat heart diseases, which are a leading cause of death worldwide. Explore the advances and challenges in using mesenchymal stem cells (MSCs) for cardiac regeneration. MSCs have shown promise in treating heart diseases, but optimal administration and the most effective MSC type still need to be determined. With ongoing research and refinement, the future looks promising for safe and effective cell-based regenerative medicine approaches in cardiac repair.s (MSCs), which can be isolated from various tissues, have been extensively studied and have shown safety and efficacy in preclinical and clinical trials for heart disease. However, there is still a lack of consensus on the optimal route of administration of MSCs and the most effective type of MSCs to use.
Several clinical trials have been conducted using MSCs to treat heart diseases such as ischemic cardiomyopathy (ICM) and non-ischemic dilated cardiomyopathy (NIDCM), and they have shown positive results in improving cardiac function and reducing scar size. In particular, the transendocardial route of injection has shown promising results in reducing scar size and improving left ventricular ejection fraction (LVEF) in both swine and human studies.
There is a need for more research to refine the manufacturing and application of MSCs, including investigating the different types of MSCs from various tissue sources and their properties, comparing different routes of administration, and exploring the potential synergy of combining MSCs with other cell types.
Despite the challenges and limitations, stem cell therapy for heart disease has progressed significantly in the past 20 years, and the future looks promising for developing safe and effective cell-based and novel cell-free regenerative medicine approaches for cardiac repair.
This is a summary of article: Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges